Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy
Authors:
Open Access
- 30 June 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 189 (2) , 521-532
Abstract
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of taxane and platinum chemotherapy for breast cancer. Clinicians cannot accurately predict CIPN severity partly because its pathophysiology is poorly understood. Although inflammation may play a role in CIPN, there are limited human studies. Here, we identified the strongest predictors of CIPN using variables measured before taxane- or platinum-based chemotherapy, including serum inflammatory markers. Methods 116 sedentary women with breast cancer (mean age 55 years) rated (1) numbness and tingling and (2) hot/coldness in hands/feet on 0–10 scales before and after 6 weeks of taxane- or platinum-based chemotherapy. A sub-study was added to collect cytokine data in the final 55 patients. We examined all linear models to predict CIPN severity at 6 weeks using pre-chemotherapy assessments of inflammatory, behavioral, clinical, and psychosocial factors. The final model was selected via goodness of fit. Results The strongest pre-chemotherapy predictors of numbness and tingling were worse fatigue/anxiety/depression (explaining 27% of variance), older age (9%), and baseline neuropathy (5%). The strongest predictors of hot/coldness in hands/feet were worse baseline neuropathy (11%) and fatigue/anxiety/depression (6%). Inflammation was a risk for CIPN, per more pro-inflammatory IFN-γ (12%) and IL-1β (6%) and less anti-inflammatory IL-10 (6%) predicting numbness/tingling and more IFN-γ (17%) and less IL-10 (9%) predicting hot/coldness in hands/feet. Conclusions The strongest pre-chemotherapy predictors of CIPN included worse fatigue/anxiety/depression and baseline neuropathy. A pro-inflammatory state also predicted CIPN. Because this is an exploratory study, these results suggest specific outcomes (e.g., IL-1β) and effect size estimates for designing replication and extension studies. Clinical trial registration: NCT00924651.Keywords
All Related Versions
Funding Information
- National Institutes of Health (U10CA037420, UG1CA189961, R25102618, T32102618, K07CA221931, K99CA237744)
This publication has 85 references indexed in Scilit:
- The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analysesCognitive Therapy and Research, 2012
- Neuromodulation therapies and treatment-resistant depressionMedical Devices: Evidence and Research, 2012
- Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1Journal of Clinical Oncology, 2011
- IFN-γ receptor signaling mediates spinal microglia activation driving neuropathic painProceedings of the National Academy of Sciences, 2009
- Educational disparities in health behaviors among patients with diabetes: the Translating Research Into Action for Diabetes (TRIAD) StudyBMC Public Health, 2007
- Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-upBritish Journal of Cancer, 2006
- The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20European Journal of Cancer, 2005
- The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigueJournal of Psychosomatic Research, 1995
- Self-Efficacy and the Stages of Exercise Behavior ChangeResearch Quarterly for Exercise and Sport, 1992
- The CES-D ScaleApplied Psychological Measurement, 1977